Block-hash of blockchain framework against man-in-the-middle attacks

Payload authentication is vulnerable to Man-in-the-middle (MITM) attack. Blockchain technology offers methods such as peer to peer, block hash, and proof-of-work to secure the payload of authentication process. The implementation uses block hash and proof-of-work methods on blockchain technology and testing is using White-box-testing and security tests distributed to system security practitioners who are competent in MITM attacks. The analyisis results before implementing Blockchain technology show that the authentication payload is still in plain text, so the data confidentiality has not minimize passive voice. After implementing Blockchain technology to the system, white-box testing using the Wireshark gives the result that the authentication payload sent has been well encrypted and safe enough. The percentage of security test results gets 95% which shows that securing the system from MITM attacks is relatively high. Although it has succeeded in securing the system from MITM attacks, it still has a vulnerability from other cyber attacks, so implementation of the Blockchain needs security improvisation

Robust Method for Semantic Segmentation of Whole-Slide Blood Cell Microscopic Image

Previous works on segmentation of SEM (scanning electron microscope) blood cell image ignore the semantic segmentation approach of whole-slide blood cell segmentation. In the proposed work, we address the problem of whole-slide blood cell segmentation using the semantic segmentation approach. We design a novel convolutional encoder-decoder framework along with VGG-16 as the pixel-level feature extraction model. -e proposed framework comprises 3 main steps: First, all the original images along with manually generated ground truth masks of each blood cell type are passed through the preprocessing stage. In the preprocessing stage, pixel-level labeling, RGB to grayscale conversion of masked image and pixel fusing, and unity mask generation are performed. After that, VGG16 is loaded into the system, which acts as a pretrained pixel-level feature extraction model. In the third step, the training process is initiated on the proposed model. We have evaluated our network performance on three evaluation metrics. We obtained outstanding results with respect to classwise, as well as global and mean accuracies. Our system achieved classwise accuracies of 97.45%, 93.34%, and 85.11% for RBCs, WBCs, and platelets, respectively, while global and mean accuracies remain 97.18% and 91.96%, respectively.Comment: 13 pages, 13 figure

Proxy Promised Signcrypion Scheme Based on Elliptic Curve Crypto System

With the rapid growth in internet technology anonymity, repudiation and smacking the contents of messages are required for illegal businesses such as money laundering etc. In this paper we design and analyze a proxy promised signcrypion scheme based on elliptic curve cryptosystem. In this system the sender/original signer can give the authority of signcrypion to another entity namely proxy signcrypter and he generates promised signcryptext on the place of sender. The scheme is accomplished aim to improve the previous crypto-systems, due to the elliptic curve small system parameter, small public key certificates, faster implementation, low power consumption and small hardware processor requirements. This ECC based scheme provides high security and efficiency

Deniable Authentication Protocol using Promised Signcrypion Based on Hyper Elliptic Curve

Anonymity and deniability has an essential role in promising internet environment. Promised signcrypion enable the sender to generate signcryptext with promised property sending it to the receiver. According to the promised property only the intended receiver can verify the original source generating the message. Hyper elliptic curve is considered suitable for constrained devices due to its lesser size key. In this paper we proposed an efficient promised signcrypion scheme based on the hardness of hyper elliptic curve discreet logarithm problem (HECDLP). We compare proposed scheme with existing scheme in term of cost (computational and communication). The proposed scheme reduces computational cost about 87.42% at sender side and 90.56% at receiver side and total communication overhead about 61.45 %. This scheme ensure the security issues like message confidentiality, message integrity, sender anonymity, authenticity

Fault-tolerant and data-intensive resource scheduling and management for scientific applications in cloud computing

Cloud computing is a fully fledged, matured and flexible computing paradigm that provides services to scientific and business applications in a subscription-based environment. Scientific applications such as Montage and CyberShake are organized scientific workflows with data and compute-intensive tasks and also have some special characteristics. These characteristics include the tasks of scientific workflows that are executed in terms of integration, disintegration, pipeline, and parallelism, and thus require special attention to task management and data-oriented resource scheduling and management. The tasks executed during pipeline are considered as bottleneck executions, the failure of which result in the wholly futile execution, which requires a fault-tolerant-aware execution. The tasks executed during parallelism require similar instances of cloud resources, and thus, cluster-based execution may upgrade the system performance in terms of make-span and execution cost. Therefore, this research work presents a cluster-based, fault-tolerant and data-intensive (CFD) scheduling for scientific applications in cloud environments. The CFD strategy addresses the data intensiveness of tasks of scientific workflows with cluster-based, fault-tolerant mechanisms. The Montage scientific workflow is considered as a simulation and the results of the CFD strategy were compared with three well-known heuristic scheduling policies: (a) MCT, (b) Max-min, and (c) Min-min. The simulation results showed that the CFD strategy reduced the make-span by 14.28%, 20.37%, and 11.77%, respectively, as compared with the existing three policies. Similarly, the CFD reduces the execution cost by 1.27%, 5.3%, and 2.21%, respectively, as compared with the existing three policies. In case of the CFD strategy, the SLA is not violated with regard to time and cost constraints, whereas it is violated by the existing policies numerous times

Proxy Signcrypion Scheme Based on Hyper Elliptic Curves

Delegation of rights is promising in Internet applications like distributed computing, e-cash systems, global distribution networks, grid computing, mobile agent applications, and mobile communications. This paper presents a novel Proxy Signcrypion Scheme based on hyper elliptic curves, attractive for resource constrained environment due to its shorter key size. It has properties of warrant integrity, message integrity, message confidentiality, warrant unforgeability, message unforgeability, proxy non repudiation and public verifiability. The proposed scheme has reduced computational cost as compared to the other existing schemes

Antimicrobial resistance among migrants in Europe: a systematic review and meta-analysis

BACKGROUND: Rates of antimicrobial resistance (AMR) are rising globally and there is concern that increased migration is contributing to the burden of antibiotic resistance in Europe. However, the effect of migration on the burden of AMR in Europe has not yet been comprehensively examined. Therefore, we did a systematic review and meta-analysis to identify and synthesise data for AMR carriage or infection in migrants to Europe to examine differences in patterns of AMR across migrant groups and in different settings. METHODS: For this systematic review and meta-analysis, we searched MEDLINE, Embase, PubMed, and Scopus with no language restrictions from Jan 1, 2000, to Jan 18, 2017, for primary data from observational studies reporting antibacterial resistance in common bacterial pathogens among migrants to 21 European Union-15 and European Economic Area countries. To be eligible for inclusion, studies had to report data on carriage or infection with laboratory-confirmed antibiotic-resistant organisms in migrant populations. We extracted data from eligible studies and assessed quality using piloted, standardised forms. We did not examine drug resistance in tuberculosis and excluded articles solely reporting on this parameter. We also excluded articles in which migrant status was determined by ethnicity, country of birth of participants' parents, or was not defined, and articles in which data were not disaggregated by migrant status. Outcomes were carriage of or infection with antibiotic-resistant organisms. We used random-effects models to calculate the pooled prevalence of each outcome. The study protocol is registered with PROSPERO, number CRD42016043681. FINDINGS: We identified 2274 articles, of which 23 observational studies reporting on antibiotic resistance in 2319 migrants were included. The pooled prevalence of any AMR carriage or AMR infection in migrants was 25·4% (95% CI 19·1-31·8; I2 =98%), including meticillin-resistant Staphylococcus aureus (7·8%, 4·8-10·7; I2 =92%) and antibiotic-resistant Gram-negative bacteria (27·2%, 17·6-36·8; I2 =94%). The pooled prevalence of any AMR carriage or infection was higher in refugees and asylum seekers (33·0%, 18·3-47·6; I2 =98%) than in other migrant groups (6·6%, 1·8-11·3; I2 =92%). The pooled prevalence of antibiotic-resistant organisms was slightly higher in high-migrant community settings (33·1%, 11·1-55·1; I2 =96%) than in migrants in hospitals (24·3%, 16·1-32·6; I2 =98%). We did not find evidence of high rates of transmission of AMR from migrant to host populations. INTERPRETATION: Migrants are exposed to conditions favouring the emergence of drug resistance during transit and in host countries in Europe. Increased antibiotic resistance among refugees and asylum seekers and in high-migrant community settings (such as refugee camps and detention facilities) highlights the need for improved living conditions, access to health care, and initiatives to facilitate detection of and appropriate high-quality treatment for antibiotic-resistant infections during transit and in host countries. Protocols for the prevention and control of infection and for antibiotic surveillance need to be integrated in all aspects of health care, which should be accessible for all migrant groups, and should target determinants of AMR before, during, and after migration. FUNDING: UK National Institute for Health Research Imperial Biomedical Research Centre, Imperial College Healthcare Charity, the Wellcome Trust, and UK National Institute for Health Research Health Protection Research Unit in Healthcare-associated Infections and Antimictobial Resistance at Imperial College London

Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial

Background: Tranexamic acid reduces surgical bleeding and reduces death due to bleeding in patients with trauma. Meta-analyses of small trials show that tranexamic acid might decrease deaths from gastrointestinal bleeding. We aimed to assess the effects of tranexamic acid in patients with gastrointestinal bleeding. Methods: We did an international, multicentre, randomised, placebo-controlled trial in 164 hospitals in 15 countries. Patients were enrolled if the responsible clinician was uncertain whether to use tranexamic acid, were aged above the minimum age considered an adult in their country (either aged 16 years and older or aged 18 years and older), and had significant (defined as at risk of bleeding to death) upper or lower gastrointestinal bleeding. Patients were randomly assigned by selection of a numbered treatment pack from a box containing eight packs that were identical apart from the pack number. Patients received either a loading dose of 1 g tranexamic acid, which was added to 100 mL infusion bag of 0·9% sodium chloride and infused by slow intravenous injection over 10 min, followed by a maintenance dose of 3 g tranexamic acid added to 1 L of any isotonic intravenous solution and infused at 125 mg/h for 24 h, or placebo (sodium chloride 0·9%). Patients, caregivers, and those assessing outcomes were masked to allocation. The primary outcome was death due to bleeding within 5 days of randomisation; analysis excluded patients who received neither dose of the allocated treatment and those for whom outcome data on death were unavailable. This trial was registered with Current Controlled Trials, ISRCTN11225767, and ClinicalTrials.gov, NCT01658124. Findings: Between July 4, 2013, and June 21, 2019, we randomly allocated 12 009 patients to receive tranexamic acid (5994, 49·9%) or matching placebo (6015, 50·1%), of whom 11 952 (99·5%) received the first dose of the allocated treatment. Death due to bleeding within 5 days of randomisation occurred in 222 (4%) of 5956 patients in the tranexamic acid group and in 226 (4%) of 5981 patients in the placebo group (risk ratio [RR] 0·99, 95% CI 0·82–1·18). Arterial thromboembolic events (myocardial infarction or stroke) were similar in the tranexamic acid group and placebo group (42 [0·7%] of 5952 vs 46 [0·8%] of 5977; 0·92; 0·60 to 1·39). Venous thromboembolic events (deep vein thrombosis or pulmonary embolism) were higher in tranexamic acid group than in the placebo group (48 [0·8%] of 5952 vs 26 [0·4%] of 5977; RR 1·85; 95% CI 1·15 to 2·98). Interpretation: We found that tranexamic acid did not reduce death from gastrointestinal bleeding. On the basis of our results, tranexamic acid should not be used for the treatment of gastrointestinal bleeding outside the context of a randomised trial

Measuring routine childhood vaccination coverage in 204 countries and territories, 1980-2019 : a systematic analysis for the Global Burden of Disease Study 2020, Release 1

Background Measuring routine childhood vaccination is crucial to inform global vaccine policies and programme implementation, and to track progress towards targets set by the Global Vaccine Action Plan (GVAP) and Immunization Agenda 2030. Robust estimates of routine vaccine coverage are needed to identify past successes and persistent vulnerabilities. Drawing from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2020, Release 1, we did a systematic analysis of global, regional, and national vaccine coverage trends using a statistical framework, by vaccine and over time. Methods For this analysis we collated 55 326 country-specific, cohort-specific, year-specific, vaccine-specific, and dosespecific observations of routine childhood vaccination coverage between 1980 and 2019. Using spatiotemporal Gaussian process regression, we produced location-specific and year-specific estimates of 11 routine childhood vaccine coverage indicators for 204 countries and territories from 1980 to 2019, adjusting for biases in countryreported data and reflecting reported stockouts and supply disruptions. We analysed global and regional trends in coverage and numbers of zero-dose children (defined as those who never received a diphtheria-tetanus-pertussis [DTP] vaccine dose), progress towards GVAP targets, and the relationship between vaccine coverage and sociodemographic development. Findings By 2019, global coverage of third-dose DTP (DTP3; 81.6% [95% uncertainty interval 80.4-82 .7]) more than doubled from levels estimated in 1980 (39.9% [37.5-42.1]), as did global coverage of the first-dose measles-containing vaccine (MCV1; from 38.5% [35.4-41.3] in 1980 to 83.6% [82.3-84.8] in 2019). Third- dose polio vaccine (Pol3) coverage also increased, from 42.6% (41.4-44.1) in 1980 to 79.8% (78.4-81.1) in 2019, and global coverage of newer vaccines increased rapidly between 2000 and 2019. The global number of zero-dose children fell by nearly 75% between 1980 and 2019, from 56.8 million (52.6-60. 9) to 14.5 million (13.4-15.9). However, over the past decade, global vaccine coverage broadly plateaued; 94 countries and territories recorded decreasing DTP3 coverage since 2010. Only 11 countries and territories were estimated to have reached the national GVAP target of at least 90% coverage for all assessed vaccines in 2019. Interpretation After achieving large gains in childhood vaccine coverage worldwide, in much of the world this progress was stalled or reversed from 2010 to 2019. These findings underscore the importance of revisiting routine immunisation strategies and programmatic approaches, recentring service delivery around equity and underserved populations. Strengthening vaccine data and monitoring systems is crucial to these pursuits, now and through to 2030, to ensure that all children have access to, and can benefit from, lifesaving vaccines. Copyright (C) 2021 The Author(s). Published by Elsevier Ltd.Peer reviewe